GenMark Diagnostics to Present at 16th Annual Needham Healthcare Conference
Get Alerts GNMK Hot Sheet
Join SI Premium – FREE
CARLSBAD, Calif.--(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, will present at the 16th Annual Needham Healthcare Conference to be held at the Westin Grand Central in New York on Wednesday, April 5, 2017. The presentation will be delivered by Hany Massarany, President and Chief Executive Officer, and is scheduled to begin at 10:40 A.M. Eastern Time. The presentation will be made available at http://ir.genmarkdx.com/.
ABOUT GENMARK DIAGNOSTICS
GenMark Diagnostics (NASDAQ: GNMK) is a leading provider of automated, multiplex molecular diagnostic testing systems that detect and measure DNA and RNA targets to diagnose disease and optimize patient treatment. Utilizing GenMark’s proprietary eSensor® detection technology, GenMark’s eSensor XT-8® system is designed to support a broad range of molecular diagnostic tests with a compact, easy-to-use workstation and self-contained, disposable test cartridges. The eSensor detection technology is also incorporated into GenMark’s new sample-to-answer system ePlex®. For more information, visit www.genmarkdx.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170328006549/en/
GenMark Diagnostics, Inc.
Hany Massarany, 760-448-4325
President,
Chief Executive Officer
Source: GenMark Diagnostics, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SkyDrive Signs Australia’s First eVTOL Agreement with Gold Coast Helitours
- Crypto News Today: AlphaPepe Presale Stages Sell Fast Before Launch Update as Cardano Price Prediction Eyes $5
- KARMAN LINE ACQUISITION CORP. Announces Pricing of $200 Million Initial Public Offering
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share